BME 312 BIOMEDICAL INSTRUMENTATION II LECTURER: ALİ IŞIN

1. FACULTY OF ENGINEERING DEPARTMENT OF BIOMEDICAL ENGINEERING BME 312 BIOMEDICAL INSTRUMENTATION IILECTURER: ALİ IŞIN LECTURE NOTE 6 Implantable Defibrillators BME 312-BMI II-L6- ALİ IŞIN 2014

2. The implantable cardioverter defibrillator (ICD) • ICD is a therapeutic device that can detect ventriculartachycardia or fibrillation and automatically deliver high-voltage (750 V) shocks that will restore normalsinus rhythm. • Advanced versions also provide low-voltage (5–10 V) pacing stimuli for painless terminationof ventricular tachycardia and for management of bradyarrhythmias. BME 312-BMI II-L6- ALİ IŞIN 2014

3. Figure 1: An Implantable Cardioverter Defibrillator and a Pacemaker BME 312-BMI II-L6- ALİ IŞIN 2014

4. The implantable defibrillator has evolved significantly since first appearing in 1980. The newest devicescan be implanted in thepatient’s pectoral region and use electrodes that can be inserted transvenously,eliminating the traumatic thoracotomy required for placement of the earlier epicardial electrode systems. BME 312-BMI II-L6- ALİ IŞIN 2014

5. Transvenous systems provide rapid, minimally invasive implants with high assurance of success andgreater patient comfort. • Advanced arrhythmia detection algorithms offer a high degree of sensitivity withreasonable specificity, and extensive monitoring is provided to document performance and to facilitateappropriate programming of arrhythmia detection and therapy parameters. • Generator longevity can nowexceed 5 years, and the cost of providing this therapy is declining. BME 312-BMI II-L6- ALİ IŞIN 2014

6. Pulse Generators • The implantable defibrillator consists of a primary battery, high-voltage capacitor bank, and sensing andcontrol circuitry housed in a hermetically sealed titanium case. BME 312-BMI II-L6- ALİ IŞIN 2014

7. Implantable defibrillator circuitry must include; • an amplifier, to allow detection of the millivolt-rangecardiac electrogram signals, • noninvasively programmable processing and control functions, to evaluatethe sensed cardiac activity and to direct generation and delivery of the therapeutic energy, • high-voltageswitching capability, • dc-dc conversion functions to step up the low battery voltages, • random accessmemories, to store appropriate patient and device data, • radiofrequency telemetry systems, to allowcommunication to and from the implanted device. BME 312-BMI II-L6- ALİ IŞIN 2014

8. Defibrillators must convert battery voltages of approximately 6.5 V to the 600–750 V needed todefibrillate the heart. • Since the conversion process cannot directly supply this high voltage at currentstrengths needed for defibrillation, charge is accumulated in relatively large ( ≈ 85–120 μ F effective capacitance) aluminum electrolytic capacitors that account for 20–30% of the volume of a typical defibrillator. • These capacitors must be charged periodically to prevent their dielectric from deteriorating. If this is notdone, the capacitors become electrically leaky, yielding excessively long charge times and delay of therapy. BME 312-BMI II-L6- ALİ IŞIN 2014

9. Power sources used in defibrillators must have sufficient capacity to provide 50–400 full energy charges (≈34 J) and 3 to 5 years of bradycardia pacing and background circuit operation. • They must have a very lowinternal resistance in order to supply the relatively high currents needed to charge the defibrillation capacitorsin 5–15 s. This generally requires that the batteries have large surface area electrodes and use chemistries thatexhibit higher rates of internal discharge than those seen with the lithium iodide batteries used in pacemakers. • The most commonly used defibrillator battery chemistry is lithium silvervanadium oxide. BME 312-BMI II-L6- ALİ IŞIN 2014

10. Electrode Systems (“Leads”) • Early implantable defibrillators utilized patch electrodes(typically a titanium mesh electrode) placed on the surfaceof the heart, requiring entry through the chest • This procedure is associated with approximately 3–4% perioperativemortality, significant hospitalization time andcomplications, patient discomfort, and high costs. Althoughsubcostal, subxiphoid, and thoracoscopic techniques canminimize the surgical procedure, the ultimate solution hasbeen development of fully transvenous lead systems with acceptable defibrillation thresholds. BME 312-BMI II-L6- ALİ IŞIN 2014

11. Figure 2: Early Epicardial ICD design with Patch Electrodes BME 312-BMI II-L6- ALİ IŞIN 2014

12. Currently available transvenous leads are constructedmuch like pacemaker leads, using polyurethane or silicone insulation and platinum-iridium electrode materials. BME 312-BMI II-L6- ALİ IŞIN 2014

13. These lead systems use a combination of two or more electrodeslocated in the right ventricular apex, the superiorvena cava, the coronary sinus, and sometimes, asubcutaneouspatch electrode is placed in the chest region. • These leads offer advantages beyond the avoidance of major surgery.They are easier to remove should there be infectionsor a need for lead system revision. BME 312-BMI II-L6- ALİ IŞIN 2014

14. Lead systems are being refined to simplify the implant procedures. One approach is the use of a singlecatheter having a single right ventricular low-voltage electrode for pacing and detection, and a pair ofhigh-voltage defibrillation electrodes spaced for replacement in the right ventricle and in the superior vena cava (Figure 3 a). A more recent approach parallels that used for unipolar pacemakers. A singleright-ventricular catheter having bipolar pace/sense electrodes and one right ventricular high-voltageelectrode is used in conjunction with a defibrillator housing that serves as the second high-voltage electrode (Figure 3 b). Mean biphasic pulse defibrillation thresholds with the generator-electrode placedin the patient’s left pectoral region are reported to be 9.8 ± 6.6 J (n = 102). This approach appears to bepracticable only with generators suitable for pectoral placement. BME 312-BMI II-L6- ALİ IŞIN 2014

15. Figure 3 a. The latest transvenous fibrillation systems employ a single catheter placed in the right ventricular apex. In panel a, a single transvenous catheter provides defibrillation electrodes in the superior vena cava and in theright ventricle. This catheter provides a single pace/sense electrode which is used in conjunction with the right ventricular high-voltage defibrillation electrode for arrhythmia detection and antibradycardia/antitachycardia pacing (configuration that is sometimes referred to asintegrated bipolar ). • Figure 3 b. With pulse generators small enough to be placedin the pectoral region, defibrillation can be achieved by delivering energy between the generator housing and onehigh-voltage electrode in the right ventricle (analogous to unipolar pacing) as is shown in panelb. This catheter provided bipolar pace/sense electrodes for arrhythmia detection and antibradycardia/antitachycardia pacing. BME 312-BMI II-L6- ALİ IŞIN 2014

16. Arrhythmia Detection • Most defibrillator detection algorithms rely primarily on heart rate to indicate the presence of a treatablerhythm. Additional refinements sometimes include simple morphology assessments, as with the probabilitydensity function, and analysis of rhythm stability and rate of change in rate. BME 312-BMI II-L6- ALİ IŞIN 2014

17. The probability density function evaluates the percentage of time that the filtered ventricular electrogramspends in a window centered on the baseline • The rate-of-change-in-rate or onset evaluation discriminates sinus tachycardia from ventricular tachycardia on the basis of the typically gradual acceleration of sinusrhythms versus the relatively abrupt acceleration of many pathologic tachycardias. BME 312-BMI II-L6- ALİ IŞIN 2014

18. The rate stability function is designed to bar detection of tachyarrhythmias as long as the variation in ventricular rateexceeds a physician-programmed tolerance, thereby reducing the likelihood of inappropriate therapydelivery in response to atrial fibrillation. • Because these additions to the detection algorithm reduce sensitivity, some defibrillator designs offera supplementary detection mode that will trigger therapy in response to any elevated ventricular rate of prolonged duration. • These extended-high-rate algorithms bypass all or portions of the normal detectionscreening, resulting in low specificity for rhythms with prolonged elevated rates such as exercise-inducedsinus tachycardia. Consequently, use of such algorithms generally increases the incidence of inappropriate therapies. BME 312-BMI II-L6- ALİ IŞIN 2014

19. Arrhythmia Therapy • Pioneering implantable defibrillators were capable only of defibrillation shocks. Subsequently, synchronizedcardioversion capability was added. Antibradycardia pacing had to be provided by implantationof a standard pacemaker in addition to thedefibrillator, and, if antitachycardia pacing was prescribed, itwas necessary to use an antitachycardia pacemaker BME 312-BMI II-L6- ALİ IŞIN 2014

20. But currently marketed implantable defibrillatorsoffer integrated ventricular demand pacemaker function and tiered antiarrhythmia therapy(pacing/cardioversion/defibrillation). • Availability of devices with antitachy pacing capability significantly increases the acceptability of the implantable defibrillatorfor patients with ventricular tachycardia. BME 312-BMI II-L6- ALİ IŞIN 2014

21. Human clinical trials have shown that biphasic defibrillation waveforms are more effective thanmonophasic waveforms, and newer devices now incorporate this characteristic. Speculative explanationsfor biphasic superiority include the large voltage change at the transition from the first to the secondphase or hyperpolarization of tissue and reactivation of sodium channels during the initial phase, withresultant tissue conditioning that allows the second phase to more readily excite the myocardium. BME 312-BMI II-L6- ALİ IŞIN 2014

22. Implantable Monitoring • Previously, defibrillator data recording capabilities were quite limited, making it difficult to verify theadequacy of arrhythmia detection and therapy settings. • The latest devices record electrograms anddiagnostic channel data showing device behavior during multiple tachyarrhythmia episodes. BME 312-BMI II-L6- ALİ IŞIN 2014

23. These devices also include counters (number of events detected, success and failure of each programmed therapy,and so on) that present a broad, though less specific, overview of device behavior (Figure 4) BME 312-BMI II-L6- ALİ IŞIN 2014

24. Figure 4 BME 312-BMI II-L6- ALİ IŞIN 2014

25. Electrogram storage has proven useful for documenting false therapy delivery due to atrial fibrillation,lead fractures, and sinus tachycardia, determining the triggers of arrhythmias; documenting rhythmaccelerations in response to therapies; and demonstrating appropriate device behavior when treating asymptomatic rhythms. BME 312-BMI II-L6- ALİ IŞIN 2014

26. Electrograms provide useful information by themselves, yet they cannot indicate how the deviceinterpreted cardiac activity. • Increasingly, electrogram records are being supplemented with event markersthat indicate how the device is responding on a beat-by-beat basis. These records can include measurementsof the sensed and paced intervals, indication as to the specific detection zone an event falls in,indication of charge initiation, and other device performance data. BME 312-BMI II-L6- ALİ IŞIN 2014

27. Follow-up • Defibrillator patients and their devices require careful follow-up. • After implantation these complications may occur ; • infection requiring device removal, • Postoperativerespiratory complications, • postoperative bleeding and/or thrombosis, • lead systemmigration or disruption, • documented inappropriate therapy delivery, most commonly due toatrial fibrillation, • transient nerve injury, • asymptomatic subclavianvein occlusion, • pericardial effusion , BME 312-BMI II-L6- ALİ IŞIN 2014

28. subcutaneous patch pocket hematoma, • Pulse generator pocket infection, • lead fracture, • lead system dislodgement. • Although routine follow-up can be accomplished in the clinic, detection and analysis of transientevents depends on the recording capabilities available in the devices or on the use of various external monitoring equipment. BME 312-BMI II-L6- ALİ IŞIN 2014

29. Conclusion • The implantable defibrillator is now an established and powerful therapeutic tool. The transition topectoral implants with biphasic waveforms and efficient yet simple transvenous and subcutaneous lead systems is simplifyingthe implant procedure. These advances are making the implantable defibrillator easierto use, less costly, and more acceptable to patients and their physicians. BME 312-BMI II-L6- ALİ IŞIN 2014